mywealthgrid
Overview
Dashboard
My workspace
My PortfolioWatchlistsFollowingScreenersAlertsResearch
Discover
CompaniesSectorsIndicesMutual fundsInstitutional investorsCompareTrade trends
Market updates
ResultsAnnouncementsSearch filingsCalendarUpcoming listings
Sign in to save your work
Sign inSign up
Loading page…
LL

Lyka Labs Limited

NSE:LYKALABSBSE:LYKALABS
HealthcarePharmaceuticals & Biotechnology
₹81.6
-2%1 Oct close
Mkt cap
₹291 Cr
Watch Alert Compare
OverviewChartPeersProfit & lossBalance sheetCash flowRatiosShareholdingF&ODocumentsEventsAnnouncementsNotes
ConsolidatedStandalone

Consolidated figures

RatioMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Margins
Gross margin %41.7%56%72.7%59.6%59.7%59.9%60.9%
EBITDA margin %-6%22.8%52.1%18.1%14.1%13%-2.7%
EBIT margin %-19%13.2%43.2%2.9%2.6%8.1%-9.3%
PAT margin %-101.9%-13.4%20.1%-14.1%-2.4%5.7%-8.1%
Working capital
Receivable days3937357989114100
Inventory days58415668788299
Payable days—14183919898122
NWC days—-63955689777
Leverage
Current ratio0.550.580.531.361.351.451.17
Debt to EBITDA—8.221.284.263.652.11—
Debt to equity7.26-6.279.721.580.840.370.52
Interest coverage-0.40.54.30.50.95.9-2.5
Asset turnover0.280.451.050.610.710.790.74
Return ratios
Return on assets %-28.3%-6.1%21%-8.7%-1.7%4.5%-6%
Return on capital employed %-5.2%8.4%75.9%5.9%3.7%10.8%-6.8%
Return on equity %-333.4%44.8%292.4%-28.9%-3.8%7.7%-11.3%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.